Generic Name and Formulations:
Droxidopa 100mg, 200mg, 300mg+; capsules; (+) contains tartrazine.
Indications for NORTHERA:
Symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Swallow whole. Take with or without food. Initially 100mg three times daily in the morning, midday, and late afternoon (≥3hrs prior to bedtime). Titrate in increments of 100mg three times daily every 24–48hrs; max 600mg three times daily.
May cause or exacerbate supine hypertension. Monitor BP (supine and head-elevated sleeping positions) prior to initiating and after increasing the dose; reduce dose or discontinue if supine hypertension persists. Monitor for symptoms of neuroleptic malignant syndrome; observe carefully during dose changes or when concomitant levodopa is reduced abruptly or discontinued, especially if receiving neuroleptics. May exacerbate ischemic heart disease, arrhythmias, CHF. Discontinue if hypersensitivity reactions occur. Allergic reactions (tartrazine). Reevaluate periodically. Severe renal impairment (GFR <30mL/min): limited data. Pregnancy. Nursing mothers: not recommended.
Concomitant drugs that increase BP (eg, norepinephrine, ephedrine, midodrine, and triptans); increased risk of supine hypertension. Concomitant dopa-decarboxylase inhibitors: may need to adjust droxidopa dose. Avoid concomitant non-selective MAOIs or linezolid.
Headache, dizziness, nausea, hypertension, falls, UTI, syncope; hyperpyrexia, confusion.
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room